Radioiodine

PreclinicalSmall molecule

Radioiodine is one of 16 small molecule programs targeting Differentiated Thyroid Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Differentiated Thyroid CarcinomaActive, not recruiting

Differentiated Thyroid CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Differentiated Thyroid Carcinoma

#DrugCompanyPhaseTrials

Mekinist

Novartis

Phase 3

1 2

Tafinlar

Novartis

Phase 3

1 3

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Approved

2 4

Cotellic

Roche

Phase 2

1 5

Lenvima

Eisai

Phase 2

1 6

Cabometyx

Bristol-Myers Squibb

Phase 2

1 7

AL2846

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 8

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 2

1 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 10

Adriamycin

GGynecologic Oncology Group

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Differentiated Thyroid Carcinoma1 trial

Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma

Recruiting·ZZhujiang Hospital·N/A·NCT04354324·254 enrolled

Treatment1 trial

Salivary dysfuncTion After Radioiodine Treatment

Completed·IInstitut de Radioprotection et de Surete Nucleaire··NCT04876287·138 enrolled

Unspecified1 trial

Dental Safety Profile of High-Dose Radioiodine Therapy

Completed·UUniversity Hospital, Basel, Switzerland··NCT00439478·202 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Radioiodine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radioiodine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radioiodine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhujiang Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZhujiang Hospital

Radioiodine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Differentiated Thyroid Carcinoma1 trial

Treatment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News